
CDC Bird Flu Response Cuts Could Lead To Another Pandemic
Bird flu remains a risk in the U.S., but we don't know as much about its threat level because the CDC stopped conducting much surveillance some time ago. They never did the kind of studies some experts had wanted.
Reported cases of bird flu are down now. Some of that may be seasonal shifts. Budget cuts at health departments likely contribute to this. More than 20% of the Veterinary Services arm of the U.S. Department of Agriculture and 16% of those in the Animal and Plant Health Inspection Service have left in response to President Trump and Elon Musk's efforts to shrink the government.
Immigrant farm workers who get bird flu symptoms are undoubtedly reluctant to seek care amid the growing ICE crackdowns and imprisonment.
The U.S. Centers for Disease Control and Prevention announced on July 7 that it was ending its emergency response for H5N1 bird flu. It will now report infections only on a monthly basis, combined with influenza activity. Infection rates in animals will no longer be reported on the CDC's page, but will be moved to the USDA's Animal and Plant Health Inspection Services avian flu page.
Infections Don't Recognize Borders
Infections may have slowed in the U.S., but since January 2025, the World Health Organization has recorded 964 cases and 466 deaths from bird flu in 24 countries.
While the CDC is dropping reporting animal infections, one should note that there is a problem on an ostrich farm in British Columbia. At least 70 of the 400 ostriches there died of bird flu this spring. Owners have resisted efforts to cull the flock, which is the standard response to an infected flock.
States have restricted the transport of infected animals across state lines, and the USDA restricts importation from countries with H5N1 infections. Showing an apparent lack of understanding of how infections spread, Robert F. Kennedy, Jr., and Dr. Mehmet Oz, now administrator of the Centers for Medicare & Medicaid Services, proposed relocating the ostriches from Canada to Oz's ranch in Okeechobee, Florida. Kennedy went so far as to appeal to the Canadian Food Inspection Agency to cancel the cull. He was unsuccessful.
Kennedy's proposal
At the same time that we are cutting surveillance, some experts are concerned that Kennedy's proposal to let bird flu spread through poultry could set us up for a pandemic. In fact, in this week's Science, several argue that this 'let 'er rip' approach would be 'dangerous and unethical.' Their concern is that by allowing the virus free rein, it will more likely spread and mutate, resulting in a pandemic. Gigi Gronvall, PhD, Johns Hopkins Center for Health Security, explains: 'The thing that we are most concerned about is that H5N1 could reassort with a circulating flu virus and gain the ability to transmit between humans. Anything we could do to reduce that likelihood, we should be doing. That includes vaccinating people against what's currently (influenza) circulating and also against H5N1.'
Angela Rasmussen, PhD, a virologist now at the University of Saskatchewan, Canada, added to Gronvall's concerns, stating in her Substack, 'If they take another tip from Kennedy and start prophylactically dosing the birds with oseltamivir (Tamiflu), this will select for viruses that are resistant to our first line class of antiviral drugs. The 'Let 'Er Rip' plan for bird flu is a really, really bad idea that will have severe health, economic, agricultural, environmental, and food security consequences. Because this plan is to basically do nothing.' She is equally scathing in her comments about surveillance (or lack thereof) and why numbers of cases are decreasing.
Vaccines For Bird Flu
There's one major problem with Gronvall's recommendation. Kennedy doesn't like these bird flu vaccines, it appears. He has stated that he believes mRNA vaccines to be dangerous and canceled the contract with Moderna to further develop the leading candidate.
The other bird flu vaccine we have in the national stockpile comes in multidose vials with the preservative thimerosal—which Kennedy's hand-picked advisory panel on vaccines voted to ban last week due to unsupported concerns that it causes autism.
We have no other options.
When I previously spoke with Saskia Popescu, Ph.D., an assistant professor of biodefense at George Mason University, she had emphasized concerns over the lack of surveillance. She and others are very worried about the impact of cuts domestic and international health efforts such as USAID, GAVI, WHO, and other global health partners. She noted, 'Global biosurveillance is a really critical resource. Early detection only happens if you are collaborating with people. And I'm very concerned that we're slowly but surely losing that capacity.'
Another of Popescu's widely shared concerns is about the growing misinformation and rejection of expertise. A recent example is the reaction to the recent new Advisory Committee on Immunization Practices recommendations, which are not evidence or science-based. Popescu noted, 'So during emergencies and any that might be coming up, we will have a population that feels unsure if they can trust any guidance that's given to them. And on top of that, I genuinely do worry that any guidance that is given to them may not be evidence based if provided from increasingly politicized non-experts.'
The fallout from Kennedy and ACIP is so bad that leading medical professional societies and a pregnant patient have just sued HHS and Kennedy for firing the ACIP committee members and replacing them unjustly. They also object to the new restrictions on COVID-19 vaccines, which would prevent healthy teens, adults, and pregnant women from receiving them. Furthermore, the American Academy of Pediatrics states that it will continue to make its own recommendations for vaccinating children. Others are following suit.
If H5N1 bird flu is allowed to spread unchecked in poultry flocks and if it
becomes easily transmissible to humans, where will the lack of surveillance, the
lack of mRNA vaccines, the banning of the non-mRNA vaccine due to its
incorporation of thimerosal, and the general mistrust of evidence-based guidance
leave us?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
3 hours ago
- The Hill
Brain-eating amoeba: Who is most often infected?
The family of a 12-year-old boy who died in South Carolina this month have confirmed his cause of death to be an infection associated with Naegleria fowleri, more commonly referred to as a ' brain-eating amoeba.' It's believed the boy, identified as Jaysen Carr, contracted the infection while swimming in Lake Murray, a central South Carolina reservoir popular with swimmers, boaters and fishermen, according to the South Carolina Department of Natural Resources. 'The family has many questions about how and why Jaysen died and wants to do everything in their power to ensure this doesn't happen to another family,' an attorney for Carr's family wrote in a statement shared with Nexstar's WCBD. What is Naegleria fowleri? Naegleria fowleri is a single-celled organism primarily found in warm freshwater and soil, according to the Centers for Disease Control and Prevention (CDC). 'It's very commonly found in nature, in soil or warm freshwater around the world … or in places where the water is warm for other reasons, like a thermal hot spring, or pool water that isn't chlorinated properly,' Dr. Dennis Kyle, a professor of infectious diseases and cellular biology at the University of Georgia and the scholar chair of antiparasitic drug discovery with the Georgia Research Alliance, once explained in an interview with Nexstar. The organisms have also been observed in improperly treated tap water, and, in lower concentrations, even cooler freshwaters. The highest concentrations, though, are generally found in freshwater with surface temperature readings of 75 degrees F or higher, especially for extended periods of time. How do infections occur? Infection of N. fowleri usually occurs after water is forced into the nose, allowing the organism to enter the nasal cavity and cross the epithelial lining into the brain, where it begins destroying the tissue of the frontal lobe, Kyle said. There's an increased risk among those who partake in freshwater activities during the warmer months, he added. 'This time of year is when we typically hear about these cases,' Kyle said of the summertime, in general. 'When people are out doing summer activities in the water, or on the lakes.' The resulting brain infection, known as primary amebic meningoencephalitis (PAM), can lead to symptoms including fever, headaches, stiff neck, seizures and hallucinations within two weeks of exposure. It is almost always fatal, with death occurring 'within about 5 days after symptoms first begin' but potentially up to a few weeks afterward, the CDC says. Can it be treated? Treatment of Naegleria fowleri infection consists of antifungal and antibiotic cocktails, and doctors have also induced hypothermia in patients to reduce fevers and protect undamaged brain tissue while the treatments are administered. Survival, however, is 'rare,' with a fatality rate estimated at about 97 percent the CDC says. Early detection and treatment can be key to improving chances, but infections may go ignored — or be misdiagnosed — until it's too late. Kyle, in a previous interview with Nexstar, said he was only aware of a handful of cases in which patients have survived, but he was optimistic about the use of collecting cerebral spinal fluid for testing purposes. Prevention (e.g., avoiding warm freshwater bodies of water, wearing nose plugs, keeping your head above water, etc.) is currently the best way to combat infection. Raising awareness of the danger also helps, Kyle said. 'But I think any warm freshwater facility, or hot spring … and at splashpads, you have to look at it carefully,' he told Nexstar. 'It's incumbent on people running these facilities to minimize risk and minimize exposure.' Who is most often infected? Anyone can contract Naegleria fowleri infection, but the CDC has identified 'young boys' as the group infected most often. 'The reasons for this aren't clear. It's possible that young boys are more likely to participate in activities like diving into the water and playing in the sediment at the bottom of lakes and rivers,' the agency said. Is climate change making infections more common? Even the CDC acknowledges that climate change may indeed be 'a contributing factor' to the conditions which allow Naegleria fowleri to thrive. 'Warmer climates means, yes, more exposure and more cases,' Kyle had said, adding that there had been a 'significant increase' in cases in recent years. But he warned that increased cases cannot be linked solely to warmer waters, but rather more awareness and fewer misdiagnoses. 'There's more recognition that these amoeba are possibly causing disease, when before, virologists were misclassifying these cases as bacterial meningitis or [other diseases],' he said.
Yahoo
3 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
3 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data